Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Novavax initiates trial of respiratory syncytial virus vaccine

PBR Staff Writer Published 05 January 2011

Novavax has initiated patient enrolment for Phase I clinical trial to evaluate the safety, immunogenicity and tolerability of a vaccine candidate against respiratory syncytial virus (RSV).

The blinded, placebo-controlled, escalating-dose will enroll 100 healthy adults 18 to 49 years old, who will be grouped into four cohorts and randomised to receive either vaccine treatment or saline placebo in a 4:1 ratio.

The interim top-line data from the trial is expected to be available in the third quarter of 2011.

Novavax president and CEO Rahul Singhvi said that the launch of this trial is timely because there are no vaccines currently approved for RSV disease.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.